Gastroparesis - Pipeline Insight, 2024

Gastroparesis - Pipeline Insight, 2024

DelveInsight’s, “Gastroparesis – Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Gastroparesis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Gastroparesis Understanding

Gastroparesis: Overview

Gastroparesis is a disease in which the stomach cannot empty itself of food in a normal fashion. This is a common condition in people who have had diabetes for a long time, but it may also occur in other situations. Gastroparesis is caused by nerve injury, including damage to the vagus nerve. In its normal state, the vagus nerve contracts (tightens) the stomach muscles to help move food through the digestive tract. In cases of gastroparesis, the vagus nerve is damaged by diabetes. This prevents the muscles of the stomach and intestine from working properly, which keeps food from moving from the stomach to the intestines. The symptoms of gastroparesis include: Heartburn or gastroesophageal reflux (backup of stomach contents into the esophagus), Nausea, Vomiting undigested food, early satiety (feeling full quickly when eating), abdominal bloating (enlargement), Poor appetite and weight loss, and Poor blood sugar control. A diagnosis of gastroparesis is made based upon a thorough clinical evaluation, a detailed patient history, and a variety of specialized tests. Tests may first be performed to rule out other causes of delayed gastric emptying such as obstruction of the gastrointestinal tract. Therapies that are used to treat individuals with gastroparesis include non-pharmacological steps, dietary modification, medications that stimulate gastric emptying (prokinetics), medications that reduce vomiting (antiemetics), medications for controlling pain and intestinal spasms, and surgery.

""Gastroparesis - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gastroparesis pipeline landscape is provided which includes the disease overview and Gastroparesis treatment guidelines. The assessment part of the report embraces, in depth Gastroparesis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastroparesis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Gastroparesis R&D. The therapies under development are focused on novel approaches to treat/improve Gastroparesis.

Gastroparesis Emerging Drugs Chapters

This segment of the Gastroparesis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Gastroparesis Emerging Drugs
• Tradipitant: Vanda Pharmaceuticals
Tradipitant is an experimental drug that is a neurokinin 1 antagonist. It works by blocking substance P, a small signaling molecule. Originally, this compound was owned by Eli Lilly and named LY686017. VLY-686 was purchased by Vanda Pharmaceuticals from Eli Lilly and Company in 2012. The drug is currently being evaluated in Phase III clinical trial to investigate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms of gastroparesis.
• Prucalopride: Janssen Inc.
Prucalopride, a selective 5-hydroxytryptamine 4 receptor agonist used in the treatment of constipation, is able to enhance the gastric emptying rate. In a Phase II double-blind, randomized, placebo-controlled crossover study, the company evaluated the efficacy of prucalopride to improve the gastric emptying rate and symptoms in patients with gastroparesis. In a cohort of patients with predominantly idiopathic gastroparesis, 4 weeks of prucalopride treatment significantly improved symptoms and quality of life and enhanced gastric emptying compared with placebo.

Further product details are provided in the report……..

Gastroparesis: Therapeutic Assessment

This segment of the report provides insights about the different Gastroparesis drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Gastroparesis
There are approx. 15+ key companies which are developing the therapies for Gastroparesis. The companies which have their Gastroparesis drug candidates in the most advanced stage, i.e. Phase III include, Vanda Pharmaceuticals.
• Phases
DelveInsight’s report covers around 15+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Gastroparesis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Gastroparesis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gastroparesis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastroparesis drugs.

Gastroparesis Report Insights
• Gastroparesis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Gastroparesis Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Gastroparesis drugs?
• How many Gastroparesis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gastroparesis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Gastroparesis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Gastroparesis and their status?
• What are the key designations that have been granted to the emerging drugs?